The use of the electromotive drug administration system in patients with superficial bladder cancer: a review of the clinical effectiveness, safety, and cost-effectiveness
CADTH
Record ID 32015000153
English
Authors' recommendations:
There is little evidence on the efficacy and safety of EDMA to treat non-muscle invasive bladder cancer. However the one article included was considered high quality and suggested administrating mitomycin via EDMA prior to transurethral tumour resection (TURBT) results in improved long term outcomes compared to TURBT alone, or passive diffusion of mitomycin post-TURBT. No evidence on the cost effectiveness of EDMA for bladder cancer was identified
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/oct-2014/RC0588%20EMDA%20for%20Bladder%20Cancer%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Urinary Bladder Neoplasms
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.